SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as speculation intensifies around a potential buyout, bolstered by a significant patent extension for its key drugs through 2042 and strong Q4 financial results. The community is actively debating the possibility of major pharma acquisition interest and the company's expanded market opportunities for IBSRELA and XPHOZAH.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a $100 million non-dilutive royalty funding agreement for its lead prostate cancer program, which is fueling investor enthusiasm around its robust oncology pipeline. The community is actively discussing the company's significant undervaluation, high short interest, and upcoming data presentations for glioblastoma and NSCLC, with many anticipating potential partnerships or a short squeeze.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly awaits its imminent BLA resubmission for Deramiocel, backed by strong HOPE-3 data, fueling widespread anticipation of accelerated approval and a significant short squeeze. Further interest stems from upcoming results for its StealthX exosome vaccine platform and ongoing discussions around the FDA's regulatory approach.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending sharply lower after its recent earnings report, which, despite strong revenue and user growth, highlighted a net loss driven by increased credit loss provisions, fueling community debate over the 'buy now, pay later' model's viability amidst broader fintech sector challenges and rising consumer debt concerns.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending on excitement over its Galleri multi-cancer early detection test, with impressive PATHFINDER 2 study results and advancing FDA submission, boosted by strategic investments from Samsung and a new partnership with Hims & Hers to expand market access. The community is actively discussing the stock's significant long-term potential fueled by upcoming regulatory approvals and legislative support for Medicare coverage.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending as it reports strong earnings that exceeded expectations, fueling community excitement over the company's perceived undervaluation amid record-high gold prices and the potential for a significant upside as precious metal miners catch up to the metal's performance. The conversation centers on its financial strength and the broader market's lag in fully pricing in the current gold rally.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean Ltd. is trending following its transformative all-stock merger with Valaris, creating a global offshore drilling powerhouse with an expanded backlog and enhanced pricing power. The community anticipates a strong earnings report and is actively discussing the potential for a short squeeze as the offshore sector experiences a multi-year resurgence.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is abuzz after securing an $11.5M defense production contract and achieving U.S. Army qualification for its advanced metal 3D printing technology. Community chatter is heavily focused on the potential for a massive short squeeze and alleged market manipulation, underscoring strong conviction in its disruptive technology and strategic partnerships with aerospace and defense leaders like SpaceX and Anduril.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai Technologies is trending as investors weigh strong Q4 results and its strategic pivot into high-growth AI-powered edge computing and cybersecurity against a cautious Q1 outlook, fueling community debate on its long-term growth trajectory.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co ($DE) is trending sharply higher after exceeding earnings expectations and boosting its full-year guidance, as management declared a bottom to the current agricultural cycle. This has ignited strong investor debate, with bulls cheering the breakout to new highs driven by strong performance in construction and small agriculture, while others question its elevated valuation and broader sector headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma (NASDAQ:XERS) Trading Down 9.3% - Should You Sell?

Xeris Biopharma (NASDAQ:XERS) Trading Down 9.3% - Here's Why...

Xeris Biopharma Holdings, Inc. $XERS Shares Sold by CenterBook Partners LP

CenterBook Partners LP decreased its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 56.2% during the third quarter, according to the company in its most recent...

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the firm, MarketBeat.com...

Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS

Y Intercept Hong Kong Ltd decreased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 75.6% during the third quarter, according to the company in its most recent filing...

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,667 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an...

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an...

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - Here's Why

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - What's Next...

John Patrick Shannon, Jr. Sells 24,907 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction that occurred on Monday, January 5th. The...

Xeris Biopharma (NASDAQ:XERS) Insider Sells $176,341.56 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Debates rage over how Corcept's loss of Korlym patent exclusivity to Teva will impact Recorlev, with many users arguing it's not a direct threat to XERS.

Traders view the sharp decline as an overreaction, seizing the "generational dip" to acquire shares at discounted prices ahead of potential recovery.

Anticipation builds for the March 2nd Q4 earnings call, with market participants expecting positive guidance and updates on the company's financial health.

Current Price	$6.72
Prev Close	$7.03
Open	$6.97
Dividend Yield	0.00%
50-Day Moving Average	$7.26
Beta	1.30
Avg. Volume	2.15M
PE Ratio	-67.99

52-Week High	$10.08
52-Week Low	$3.58
Market Capitalization	$1.17B
EPS (Annual)	-$0.3736
Price to Book	-1,351.92
Revenue Per Employee	$515,406.09

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XERS News

XERSXeris Biopharma Holdings Inc